Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Modafinil · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | docetaxel chemotherapy + modafinil 100 mg capsules |
| 2 | PLACEBO_COMPARATOR | docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug) |
| Name | Type | Description |
|---|---|---|
| DOCETAXEL(XRP6976) + MODAFINIL | DRUG | arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily |
| Modafinil | DRUG | best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily |
| Placebo of Modafinil | DRUG | Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon) |
Inclusion criteria: * Treatment with q3w (every three weeks) docetaxel-based chemotherapy for metastatic breast or prostate cancer at a minimum dose of 50 mg/m2 * Completed at least two cycles of chemotherapy and intention to treat the patient with at least two further cycles of docetaxel-based che...
Modafinil is being studied for use in prostatic neoplasms, specifically in patients treated with docetaxel-based chemotherapy for metastatic prostate cancer. It is an investigational small molecule in Phase 3 clinical development for this oncology indication, though it is not yet approved for this use.
Modafinil is being developed by Sanofi, a company traded under the ticker SNY. Sanofi is conducting clinical research on this small molecule for oncology applications, including its potential use in patients with prostatic neoplasms.
Modafinil is in Phase 3 clinical development for prostatic neoplasms. The drug is investigational and has not been approved for this indication. A Phase 3 study has been completed, but the drug remains in clinical development.
Modafinil has one completed Phase 3 clinical trial, identified as NCT00917748, titled "Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)." This randomized, double-blind, placebo-controlled trial enrolled 84 participants and was conducted in Australia.
Modafinil is the generic name for the drug also known as Provigil. In the context of prostatic neoplasms, it is being investigated as an adjunct to docetaxel-based chemotherapy, though it is not approved for this oncology use.